logo-loader

OncoCyte looks to begin R&D validation stage for its cancer diagnostics test

Published: 15:04 18 Oct 2018 EDT

OncoCyte Corporation (NYSE:OCX) CEO William Annett sat down with Christine Corrado at the BIO Investor Forum in San Francisco.

OncoCyte is focused on the discovery, development and commercialization of liquid biopsy diagnostics for early cancer detection.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 6 minutes ago